Article
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer.
Current pharmaceutical design - 1 Jan 2013
Galvani Elena, Alfieri Roberta, Giovannetti Elisa, Cavazzoni Andrea, La Monica Silvia, Galetti Maricla, Fumarola Claudia, Bonelli Mara, Mor Marco, Tiseo Marcello, Peters Godefridus J, Petronini Pier Giorgio, Ardizzoni Andrea
Abstract excerpt
Conventional chemotherapeutic regimens have reached an efficacy plateau against most solid tumors and deal with significant toxicity. Recently, the goal of oncologic research to improve outcome and reduce treatment-related side-effects has led to the development of novel anticancer treatments tar...
Topics
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Disease Progression
- Drug Design
- Drug Resistance, Neoplasm
- ErbB Receptors
- Humans
- Lung Neoplasms
- Molecular Targeted Therapy
- Mutation
- Point Mutation
- Protein Kinase Inhibitors